INS and type 2 diabetes mellitus: ORBIT—a multicenter, prospective, 6-month registry-based study conducted in China—showed that persons with T2DM previously inadequately controlled on OADs, following initiation of basal insulin analogues, experienced a mean reduction in HbA1c of 2%, with 48% of participants achieving treatment targets [13].